{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010303","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.445534+00:00","generated_at":"2026-06-04T15:30:41.679409+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance","bullets":["Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.","Cash, equivalents and marketable securities $41.3M at Dec 31, 2023, down from $55.2M a year earlier.","LP-184 Phase 1A continuing; initial readout expected late summer/early fall 2024. LP-284 Phase 1 dosed first patients.","Starlight Therapeutics hired CMO; plans Phase 1B/2 CNS trial in H2 2024. RADR platform surpassed 60B datapoints.","Share repurchase of 145,348 shares at $3.44/sh in November 2023 reduced outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010303","json":"https://secwatch.observer/filing/0001493152-24-010303.json","markdown":"https://secwatch.observer/filing/0001493152-24-010303.md","text":"https://secwatch.observer/filing/0001493152-24-010303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/0001493152-24-010303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:30:41.679409+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61cf6ca63ebb97b4e4115b92e138e3db1295fad8","claim":"Lantern Pharma Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On March 18, 2024, Lantern Pharma Inc. (the \"Company\") will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/0001493152-24-010303-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}